VLA15 is the only active Lyme disease vaccine candidate in clinical development today, covering six serotypes of Lyme disease prevalent in North America and Europe. It was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 2017. In a few months, Valneva expects to report top-line results for the second Phase 2 study, VLA15-202. Valneva and Pfizer are collaborating
for development and commercialization of VLA15.
Read full July 22, 2020 press release here
Read Valneva vaccine history and Lyme Disease Association’s concerns here: